TG Therapeutics, Inc. (0VGI.L)
USD 31.97
(-5.69%)
USD 31.97
(-5.69%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 329.58 Million USD | 70.27% |
| 2022 | 193.57 Million USD | -49.01% |
| 2021 | 379.62 Million USD | -39.32% |
| 2020 | 625.64 Million USD | 283.8% |
| 2019 | 163.01 Million USD | 94.96% |
| 2018 | 83.61 Million USD | -14.14% |
| 2017 | 97.38 Million USD | 77.76% |
| 2016 | 54.78 Million USD | -51.72% |
| 2015 | 113.47 Million USD | 30.81% |
| 2014 | 86.74 Million USD | 80.3% |
| 2013 | 48.11 Million USD | 117.96% |
| 2012 | 22.07 Million USD | 38.77% |
| 2011 | 15.9 Million USD | -14.64% |
| 2010 | 18.63 Million USD | 4996.41% |
| 2009 | 365.66 Thousand USD | -70.72% |
| 2008 | 1.24 Million USD | 27.37% |
| 2007 | 980.57 Thousand USD | -71.56% |
| 2006 | 3.44 Million USD | -69.23% |
| 2005 | 11.2 Million USD | 98.36% |
| 2004 | 5.64 Million USD | -27.56% |
| 2003 | 7.79 Million USD | 3010.37% |
| 2002 | 250.74 Thousand USD | -85.74% |
| 2001 | 1.75 Million USD | -44.65% |
| 2000 | 3.17 Million USD | -20.59% |
| 1999 | 4 Million USD | -38.46% |
| 1998 | 6.5 Million USD | -26.14% |
| 1997 | 8.8 Million USD | 266.67% |
| 1996 | 2.4 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 401.2 Million USD | 7.47% |
| 2024 Q1 | 373.32 Million USD | 13.27% |
| 2023 Q3 | 331.06 Million USD | 49.9% |
| 2023 Q2 | 220.85 Million USD | 11.91% |
| 2023 FY | 329.58 Million USD | 70.27% |
| 2023 Q4 | 329.58 Million USD | -0.45% |
| 2023 Q1 | 197.35 Million USD | 1.96% |
| 2022 FY | 193.57 Million USD | -49.01% |
| 2022 Q4 | 193.57 Million USD | -11.16% |
| 2022 Q1 | 303.02 Million USD | -20.18% |
| 2022 Q2 | 251.66 Million USD | -16.95% |
| 2022 Q3 | 217.89 Million USD | -13.42% |
| 2021 Q2 | 481.4 Million USD | -12.27% |
| 2021 Q3 | 409.68 Million USD | -14.9% |
| 2021 Q4 | 379.62 Million USD | -7.34% |
| 2021 FY | 379.62 Million USD | -39.32% |
| 2021 Q1 | 548.69 Million USD | -12.3% |
| 2020 Q3 | 273.85 Million USD | -7.05% |
| 2020 Q4 | 625.64 Million USD | 128.46% |
| 2020 FY | 625.64 Million USD | 283.8% |
| 2020 Q2 | 294.62 Million USD | 189.27% |
| 2020 Q1 | 101.84 Million USD | -37.52% |
| 2019 Q1 | 117.53 Million USD | 40.57% |
| 2019 Q4 | 163.01 Million USD | 74.67% |
| 2019 Q3 | 93.32 Million USD | -12.44% |
| 2019 Q2 | 106.58 Million USD | -9.32% |
| 2019 FY | 163.01 Million USD | 94.96% |
| 2018 Q1 | 120.99 Million USD | 24.25% |
| 2018 FY | 83.61 Million USD | -14.14% |
| 2018 Q4 | 83.61 Million USD | -26.89% |
| 2018 Q3 | 114.37 Million USD | -18.72% |
| 2018 Q2 | 140.71 Million USD | 16.3% |
| 2017 Q3 | 101.78 Million USD | 0.58% |
| 2017 Q2 | 101.19 Million USD | -17.9% |
| 2017 Q1 | 123.25 Million USD | 125.0% |
| 2017 Q4 | 97.38 Million USD | -4.32% |
| 2017 FY | 97.38 Million USD | 77.76% |
| 2016 Q4 | 54.78 Million USD | -27.62% |
| 2016 Q3 | 75.68 Million USD | -20.16% |
| 2016 Q2 | 94.79 Million USD | -5.26% |
| 2016 Q1 | 100.06 Million USD | -11.82% |
| 2016 FY | 54.78 Million USD | -51.72% |
| 2015 Q4 | 113.47 Million USD | -10.94% |
| 2015 FY | 113.47 Million USD | 30.81% |
| 2015 Q1 | 117.26 Million USD | 35.19% |
| 2015 Q2 | 123.6 Million USD | 5.4% |
| 2015 Q3 | 127.4 Million USD | 3.08% |
| 2014 Q2 | 56.3 Million USD | -3.22% |
| 2014 Q1 | 58.17 Million USD | 20.91% |
| 2014 Q4 | 86.74 Million USD | 11.87% |
| 2014 FY | 86.74 Million USD | 80.3% |
| 2014 Q3 | 77.54 Million USD | 37.73% |
| 2013 Q3 | 54.29 Million USD | 204.05% |
| 2013 FY | 48.11 Million USD | 117.96% |
| 2013 Q4 | 48.11 Million USD | -11.39% |
| 2013 Q2 | 17.85 Million USD | -16.5% |
| 2013 Q1 | 21.38 Million USD | -3.11% |
| 2012 FY | 22.07 Million USD | 38.77% |
| 2012 Q1 | 27.07 Million USD | 70.2% |
| 2012 Q3 | 25.23 Million USD | -4.89% |
| 2012 Q2 | 26.52 Million USD | -2.01% |
| 2012 Q4 | 22.07 Million USD | -12.51% |
| 2011 Q3 | 18.06 Million USD | -1.62% |
| 2011 Q4 | 15.9 Million USD | -11.94% |
| 2011 Q1 | 18.65 Million USD | 0.1% |
| 2011 Q2 | 18.36 Million USD | -1.57% |
| 2011 FY | 15.9 Million USD | -14.64% |
| 2010 Q1 | 20.08 Million USD | 5391.92% |
| 2010 FY | 18.63 Million USD | 4996.41% |
| 2010 Q4 | 18.63 Million USD | -2.1% |
| 2010 Q3 | 19.03 Million USD | -2.85% |
| 2010 Q2 | 19.59 Million USD | -2.43% |
| 2009 Q3 | 682.55 Thousand USD | -40.1% |
| 2009 Q1 | 1.56 Million USD | 25.06% |
| 2009 Q4 | 365.66 Thousand USD | -46.43% |
| 2009 Q2 | 1.13 Million USD | -27.05% |
| 2009 FY | 365.66 Thousand USD | -70.72% |
| 2008 Q3 | 204.9 Thousand USD | -78.95% |
| 2008 FY | 1.24 Million USD | 27.37% |
| 2008 Q1 | 1.48 Million USD | 51.69% |
| 2008 Q2 | 973.34 Thousand USD | -34.56% |
| 2008 Q4 | 1.24 Million USD | 509.55% |
| 2007 Q1 | 9.33 Million USD | 170.78% |
| 2007 FY | 980.57 Thousand USD | -71.56% |
| 2007 Q3 | 2.35 Million USD | -55.32% |
| 2007 Q4 | 980.57 Thousand USD | -58.41% |
| 2007 Q2 | 5.27 Million USD | -43.48% |
| 2006 Q4 | 3.44 Million USD | -35.14% |
| 2006 FY | 3.44 Million USD | -69.23% |
| 2006 Q3 | 5.31 Million USD | -30.85% |
| 2006 Q2 | 7.68 Million USD | -17.11% |
| 2006 Q1 | 9.27 Million USD | -17.23% |
| 2005 Q3 | 13.07 Million USD | 402.99% |
| 2005 FY | 11.2 Million USD | 98.36% |
| 2005 Q1 | 4.39 Million USD | -22.27% |
| 2005 Q2 | 2.59 Million USD | -40.81% |
| 2005 Q4 | 11.2 Million USD | -14.28% |
| 2004 Q3 | 7.62 Million USD | -14.78% |
| 2004 Q4 | 5.64 Million USD | -25.91% |
| 2004 Q2 | 8.94 Million USD | -10.15% |
| 2004 Q1 | 9.95 Million USD | 27.68% |
| 2004 FY | 5.64 Million USD | -27.56% |
| 2003 Q3 | 529.13 Thousand USD | -85.32% |
| 2003 Q2 | 3.6 Million USD | -17.6% |
| 2003 Q1 | 4.37 Million USD | 1644.57% |
| 2003 FY | 7.79 Million USD | 3010.37% |
| 2003 Q4 | 7.79 Million USD | 1373.89% |
| 2002 Q2 | 1.05 Million USD | -1.12% |
| 2002 Q3 | 547.63 Thousand USD | -48.25% |
| 2002 FY | 250.74 Thousand USD | -85.74% |
| 2002 Q4 | 250.74 Thousand USD | -54.21% |
| 2002 Q1 | 1.07 Million USD | -39.14% |
| 2001 Q4 | 1.75 Million USD | 185.77% |
| 2001 Q1 | 2.95 Million USD | -6.93% |
| 2001 Q2 | 1.22 Million USD | -58.41% |
| 2001 Q3 | 615.3 Thousand USD | -49.96% |
| 2001 FY | 1.75 Million USD | -44.65% |
| 2000 Q3 | 3.08 Million USD | 15.35% |
| 2000 Q1 | 3.84 Million USD | -3.83% |
| 2000 Q2 | 2.67 Million USD | -30.42% |
| 2000 Q4 | 3.17 Million USD | 2.88% |
| 2000 FY | 3.17 Million USD | -20.59% |
| 1999 Q2 | 4.7 Million USD | -11.32% |
| 1999 Q3 | 4.2 Million USD | -10.64% |
| 1999 Q4 | 4 Million USD | -4.76% |
| 1999 FY | 4 Million USD | -38.46% |
| 1999 Q1 | 5.3 Million USD | -18.46% |
| 1998 Q3 | 7.7 Million USD | -12.5% |
| 1998 FY | 6.5 Million USD | -26.14% |
| 1998 Q4 | 6.5 Million USD | -15.58% |
| 1998 Q1 | 7.4 Million USD | -15.91% |
| 1998 Q2 | 8.8 Million USD | 18.92% |
| 1997 Q4 | 8.8 Million USD | -13.73% |
| 1997 Q1 | 1.6 Million USD | -33.33% |
| 1997 FY | 8.8 Million USD | 266.67% |
| 1997 Q2 | 2.5 Million USD | 56.25% |
| 1997 Q3 | 10.2 Million USD | 308.0% |
| 1996 Q3 | 3.5 Million USD | 20.69% |
| 1996 Q4 | 2.4 Million USD | -31.43% |
| 1996 FY | 2.4 Million USD | 0.0% |
| 1996 Q2 | 2.9 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | 60.371% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 64.83% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 57.63% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -99.141% |
| bluebird bio, Inc. | 619.16 Million USD | 46.769% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -161.901% |
| Imunon, Inc. | 21.91 Million USD | -1403.723% |
| Editas Medicine, Inc. | 499.15 Million USD | 33.971% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 98.765% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 90.178% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 72.505% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 89.863% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 76.608% |
| Verastem, Inc. | 149.71 Million USD | -120.139% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.593% |
| Waters Corporation | 4.62 Billion USD | 92.877% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.666% |
| Biogen Inc. | 26.84 Billion USD | 98.772% |
| Nektar Therapeutics | 398.03 Million USD | 17.196% |
| Perrigo Company plc | 10.8 Billion USD | 96.951% |
| Dynavax Technologies Corporation | 997.09 Million USD | 66.945% |
| Illumina, Inc. | 10.11 Billion USD | 96.74% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1065.756% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 57.764% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -48.125% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -401.731% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 95.183% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -99.363% |
| Evolus, Inc. | 188.99 Million USD | -74.387% |
| Adicet Bio, Inc. | 207.29 Million USD | -58.994% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -66.96% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.004% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -60.152% |
| FibroGen, Inc. | 423.52 Million USD | 22.181% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 96.938% |
| OPKO Health, Inc. | 2.01 Billion USD | 83.616% |
| Homology Medicines, Inc. | 47.05 Million USD | -600.4% |
| Geron Corporation | 394.07 Million USD | 16.365% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 91.394% |
| Exelixis, Inc. | 2.94 Billion USD | 88.799% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 10.557% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -113.482% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 74.666% |
| Zoetis Inc. | 14.28 Billion USD | 97.693% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 43.97% |
| Abeona Therapeutics Inc. | 64 Million USD | -414.964% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 98.55% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -489.085% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 88.977% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 89.904% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 46.971% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 80.985% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 68.588% |
| Insmed Incorporated | 1.32 Billion USD | 75.216% |
| Incyte Corporation | 6.78 Billion USD | 95.14% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 82.038% |